UPCOMING EVENTS
NEWS
KaloCyte Closes Investment from New York Blood Center
KaloCyte, Inc., a developer of bio-inspired red blood cell substitute ErythroMer™, announced it has closed an investment from New York Blood Center, Inc. (NYBC).
KaloCyte with the Angel Capital Association – Innovation Showcase Winners
Mark it on your calendar! On June 9, at 4:00 PM EST, our KaloCyte will join other Innovation Showcase winners pitching again in an exclusive online event in which each winner, chosen by ACA Summit attendees, will have 10 minutes to pitch.
A Strategic Relocation to Baltimore Supports one Biomedical Company’s Growth
KaloCyte’s Co-founders made the best of both worlds right in the heart of Baltimore: The St. Louis-founded startup moved into CBOTH as a University of Maryland BioPark affiliate in July 2019.
The Washington Post – Synthetic Blood Substitute Research Advances Rapidly
One of KaloCyte’s co-founders, Dr. Allan Doctor, was among several experts interviewed for and quoted in the article on synthetic blood research, and KaloCyte’s ErythroMer and developmental status is featured
BioGenerator Highlights KaloCyte Case Study
BioGenerator leveraged its Grants, Fundamentals, and Grants- 2-Business programs enabling KaloCyte to craft and implement three highly innovative strategies (technical differentiation, accelerating regulatory path, Federal de-risking grants) to attract expertise and funding.
KaloCyte in the News: UMB Startups Receive Support from Maryland Momentum Fund
The University System of Maryland (USM) continues to aid entrepreneurs at UMB and throughout the state, including KaloCyte, with the $10 million Maryland Momentum Fund (MMF).
KaloCyte in the News: Old Line Capital Invests in KaloCyte
Old Line Capital Partners has made a significant investment in KaloCyte, Inc., to extend the research and development of break-through human blood substitute ErythroMer.
KaloCyte in the News: KaloCyte raises $300K from Maryland Momentum Fund
Months after moving to Baltimore, the company is growing its team and gaining funding from local institutions.
Press Release: KaloCyte, Inc., selected for Springboard’s Health Innovation Hub, Joins Network of more than 800 Seasoned Entrepreneurs
Elaine Haynes, president and CEO of KaloCyte, will join more than 800 experienced “been there, run that” entrepreneurs who make up the Springboard Expert Network.
Press Release: NIH Awards KaloCyte $373K SBIR Grant to Advance Synthetic Blood Product
The NIH SBIR grant will help KaloCyte develop ErythroMer™ to preclinical safety and efficacy testing.
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by over $20M in federal grants and investor funding.